@article{a402aa19c78b405a9a783de6331ff09e,
title = "Preclinical Alzheimer's disease and longitudinal driving decline",
abstract = "Introduction Links between preclinical Alzheimer's disease (AD) and driving difficulty onset would support the use of driving performance as an outcome in primary and secondary prevention trials among older adults (OAs). We examined whether AD biomarkers predicted the onset of driving difficulties among OAs. Methods One hundred four OAs (65+ years) with normal cognition took part in biomarker measurements, a road test, clinical and psychometric batteries, and self-reported their driving habits. Results Higher values of cerebrospinal fluid (CSF) tau/Aβ42 and phosphorylated tau (ptau181)/Aβ42 ratios, but not uptake on Pittsburgh compound B amyloid imaging (P =.12), predicted time to a rating of marginal or fail on the driving test using Cox proportional hazards models. Hazards ratios (95% confidence interval) were 5.75 (1.70–19.53), P =.005 for CSF tau/Aβ42; 6.19 (1.75–21.88), and P =.005 for CSF ptau181/Aβ42. Discussion Preclinical AD predicted time to receiving a marginal or fail rating on an on-road driving test. Driving performance shows promise as a functional outcome in AD prevention trials.",
keywords = "Aged, Alzheimer's disease, Amyloid imaging, Biomarker, Cerebrospinal fluid, Driving, Functional outcome, Older adults, Preclinical, Ptau, Road test, Tau",
author = "Roe, {Catherine M.} and Babulal, {Ganesh M.} and Head, {Denise M.} and Stout, {Sarah H.} and Vernon, {Elizabeth K.} and Nupur Ghoshal and Brad Garland and Barco, {Peggy P.} and Williams, {Monique M.} and Ann Johnson and Rebecca Fierberg and Fague, {M. Scot} and Chengjie Xiong and Elizabeth Mormino and Grant, {Elizabeth A.} and Holtzman, {David M.} and Benzinger, {Tammie L.S.} and Fagan, {Anne M.} and Ott, {Brian R.} and Carr, {David B.} and Morris, {John C.}",
note = "Funding Information: Funding for this study was provided by the National Institute on Aging (R01AG043434, R01AG43434-03S1, P50AG005681, P01AG003991, and P01AG026276); Fred Simmons and Olga Mohan, the Farrell Family Research Fund, and the Charles and Joanne Knight Alzheimer's Research Initiative of the Washington University Knight Alzheimer's Disease Research Center (ADRC). The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the article. The authors thank the participants, investigators, and staff of the Knight ADRC Clinical Core for participant assessments, Genetics Core for APOE genotyping, Biomarker Core for cerebrospinal fluid analysis, and the Imaging Core for amyloid imaging. Imaging facilities were supported by the Washington University Institute of Clinical and Translational Sciences grant UL1TR000448 from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH). Imaging analyses used the services of the Neuroimaging Informatics and Analysis Center, supported by NIH grant 5P30NS048056. Catherine M. Roe had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Publisher Copyright: {\textcopyright} 2016 The Authors",
year = "2017",
month = jan,
day = "1",
doi = "10.1016/j.trci.2016.11.006",
language = "English",
volume = "3",
pages = "74--82",
journal = "Alzheimer's and Dementia: Translational Research and Clinical Interventions",
issn = "2352-8737",
number = "1",
}